HCPLive

AUGUST 1, 2024

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

Heart Failure 69

Heart Failure Obesity Outcomes 69

Science Daily - Heart Disease

NOVEMBER 20, 2024

Weight-loss and diabetes drug tirzepatide can reduce the risk of death or worsening heart failure for patients with obesity and heart failure with preserved pump function, new research reveals.

Heart Failure 95

Heart Failure Obesity Diabetes Research 95

Cardiovascular Diabetology

AUGUST 13, 2024

Heart failure with preserved ejection fraction (HFpEF) is associated with systemic inflammation, obesity, metabolic syndrome, and gut microbiome changes. Increased trimethylamine-N-oxide (TMAO) levels are pred.

Preserved Ejection Fraction 103

Preserved Ejection Fraction Heart Failure Obesity Research 103

Med Page Today

OCTOBER 2, 2024

(MedPage Today) -- The novel investigational weight loss agent HU6 had mixed results specifically targeting obesity-related heart failure with preserved ejection fraction (HFpEF), based on the small HuMain-HFpEF trial. After 19 weeks on daily.

Preserved Ejection Fraction 96

Preserved Ejection Fraction Obesity Heart Failure 96

American College of Cardiology

APRIL 6, 2024

The goal of the STEP-HFpEF DM trial was to compare the safety and efficacy of semaglutide among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (DM).

Preserved Ejection Fraction 69

Preserved Ejection Fraction Heart Failure Obesity Diabetes 69

DAIC

JULY 31, 2024

mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).

Heart Failure 111

Heart Failure Preserved Ejection Fraction Research Hospital 111

HCPLive

NOVEMBER 19, 2024

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Heart Failure 118

Heart Failure Obesity 118

American College of Cardiology

NOVEMBER 16, 2024

In patients with obesity and heart failure with preserved ejection fraction (HFpEF), weekly treatment with tirzepatide over approximately two years reduced the risk of worsening heart failure events, based on findings from the SUMMIT trial.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Quality of Life Obesity Heart Failure 75

Frontiers in Cardiovascular Medicine

DECEMBER 13, 2023

Background The obesity occurrence has achieved epidemic levels worldwide and several studies indicate a paradoxical similarity among obesity and the prognosis in heart failure (HF). Conclusion In not hospitalized patients with HFREF of ischemic etiology, obesity was not a protective factor.

Outpatient 59

Outpatient Obesity Heart Failure BMI 59

JAMA Cardiology

NOVEMBER 15, 2024

In this case series study, pulmonary artery systolic, diastolic, and mean pressures of 2 participants with obesity and heart failure with preserved ejection fraction were measured at zero gravity during parabolic flight to assess the effect of external constraint on left ventricular filling pressures.

Preserved Ejection Fraction 63

Preserved Ejection Fraction Heart Failure Obesity Pulmonary 63

American College of Cardiology

DECEMBER 13, 2023

Obesity is quite common in patients suffering from heart failure with preserved ejection fraction (HFpEF). Semaglutide is a glucagon-like peptide-1 receptor agonist that has been shown to cause weight loss and reduce cardiovascular events in patients with obesity.

Preserved Ejection Fraction 63

Preserved Ejection Fraction Heart Failure Obesity Article 63

American College of Cardiology

JANUARY 8, 2024

Obesity is a multifaceted disease that is directly and indirectly implicated in atherosclerotic cardiovascular disease (CVD), heart failure (HF), atrial fibrillation (AF), and multiple CVD risk factors, including dyslipidemia, hypertension, type 2 diabetes mellitus (DM), and sleep disorders.

Obesity 71

Obesity Atrial Fibrillation Risk Factors Heart Failure 71

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 60

Preserved Ejection Fraction Obesity Heart Failure Diabetes 60

American College of Cardiology

NOVEMBER 16, 2024

The goal of the SUMMIT trial was to compare the safety and efficacy of tirzepatide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 48

Preserved Ejection Fraction Heart Failure Obesity Article 48

American College of Cardiology

JULY 16, 2024

For patients with obesity-related heart failure with preserved ejection fraction (HFpEF), what is the effect of semaglutide on change in New York Heart Association (NYHA) functional class over time?

Preserved Ejection Fraction 60

Preserved Ejection Fraction Obesity Heart Failure Article 60

American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 60

Obesity Pulmonary Hypertension TAVR 60

Becker's Hospital Review - Cardiology

NOVEMBER 18, 2024

The GLP-1 tirzepatide, the active ingredient in Eli Lilly's Mounjaro, was found to reduce the risk of heart failure by 46% among individuals with obesity, according to a study published Nov. 16 in The New England Journal of Medicine and presented at the American Heart Association's annual Scientific Sessions.

Heart Failure 59

Heart Failure Obesity 59

Cardiovascular Diabetology

SEPTEMBER 10, 2024

Although the “obesity paradox” is comprehensively elucidated in heart failure (HF) with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF), the role of body composition in left v.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Obesity Outcomes 52

Open Heart

MAY 23, 2024

Pre-eclampsia and heart failure have common risk factors, including hypertension, obesity and diabetes. It is not known whether heart failure increases the risk of pre-eclampsia. This study examines whether pregestational heart failure increases the risk of pre-eclampsia.

Heart Disease 98

Heart Disease Heart Failure Risk Factors Obesity 98

American College of Cardiology

AUGUST 26, 2024

The goal of the STEP-HFpEF trial was to compare the safety and efficacy of semaglutide among patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

Preserved Ejection Fraction 56

Preserved Ejection Fraction Obesity Heart Failure Article 56

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 65

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 65

Frontiers in Cardiovascular Medicine

JULY 17, 2024

Recently, indisputable evidence has shown that the TyG index is strongly associated with cardiovascular disease [CVD, including atherosclerosis, heart failure (HF), and hypertension] prognosis and mortality. Finally, we summarized the mechanism of the “obesity paradox.”

Heart Failure 64

Heart Failure Atherosclerosis Biomarkers Obesity 64

Cardiometabolic Health Congress

NOVEMBER 14, 2024

42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Ndumele provided an in-depth analysis of cardiac biomarkers and their role in cardiovascular risk prediction and heart failure (HF) management at the 19th Annual CMHC. In the U.S.,

CME 103

CME Obesity Heart Failure Biomarkers 103

Becker's Hospital Review - Cardiology

NOVEMBER 7, 2024

Semaglutide treatment was found to reduce healthcare costs significantly for patients with overweight or obesity and who had either heart failure or atherosclerotic cardiovascular disease, according to studies presented Nov. 3-6 at the Obesity Society's annual Obesity Week conference and reviewed Nov.

Heart Failure 52

Heart Failure Obesity Cardiovascular Disease 52

European Journal of Heart Failure

DECEMBER 22, 2023

Abstract Background N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations are lower in patients with obesity. The interaction between body mass index (BMI) and NT-proBNP with respect to heart failure (HF) risk remains incompletely defined.

Heart Failure 75

Heart Failure BMI Obesity Article 75

HeartRhythm

APRIL 30, 2024

Catheter Ablation for Atrial Fibrillation (AFib) in heart failure is now a class I indication for patients with heart failure. Evidence supports the relationship between obesity and the incidence and recurrence of Afib.

Atrial Fibrillation 40

Atrial Fibrillation Heart Failure Obesity Ablation 40

Journal of Clinical Investigation - Cardiology

DECEMBER 15, 2023

Heart failure with preserved ejection fraction (HFpEF) is a widespread syndrome with limited therapeutic options and poorly understood immune pathophysiology.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Obesity Ablation 75

Frontiers in Cardiovascular Medicine

DECEMBER 17, 2023

These conditions have an increasing share in the health burden worldwide due to worsening endemic of hypertension, obesity, and diabetes. However, the same set of genes were significantly induced in the Trp53inp2-cKO hearts under both mechanical and metabolic stresses.

Heart Failure 64

Heart Failure Diet Obesity Diabetes 64

HeartRhythm

APRIL 30, 2024

We have previously shown an association between metabolic syndrome (MS) and heart failure (HF) outcomes in patients with implanted defibrillators (ICD) and cardiac resynchronization therapy (CRT-D). However, the role of MS and diabetes in predicting HF outcomes was not assessed in non-obese patients.

Heart Failure 40

Heart Failure Obesity Diabetes Outcomes 40

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′. Overall, 60.9%

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Cardiology Update

DECEMBER 11, 2023

Previous studies have associated obesity with negative changes in the right ventricle using imaging techniques. However, the connection between obesity and more direct measures of right ventricle function, particularly those reflecting hemodynamic consequences, have been unclear. Original article: Circ Heart Fail.

Obesity 52

Obesity Hospital Outcomes Heart Failure 52

Circulation

NOVEMBER 17, 2024

Background: Patients with heart failure, a preserved ejection fraction (HFpEF), and obesity have significant disability and suffer frequent exacerbations of heart failure. 6MWD 302.881.7meters, and 53%(n=388) had a worsening heart failure event in the prior 12 months. Circulation, Ahead of Print.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Obesity Quality of Life 40

American College of Cardiology

NOVEMBER 5, 2024

The idea that obesity increases the risk of heart failure seems like an obvious conclusion. After all, as the Framingham Heart Study clearly showed, obesity and overweight are significantly associated with a higher risk of hypertension, angina and coronary heart disease.

Heart Failure 44

Heart Failure Innovation Angina Obesity 44

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Objectives In dyspneic patients with atrial fibrillation (AF) or obesity, the diagnostic performance of NT-proBNP for acute heart failure is reduced. The diagnostic performance of ERFE is impaired in patients with AF but not patients with obesity.

Heart Failure 59

Heart Failure Circulation Obesity Atrial Fibrillation 59

Circulation: Heart Failure

JANUARY 26, 2024

Circulation: Heart Failure, Ahead of Print.

Heart Failure 40

Heart Failure Pharmacology Obesity Outcomes 40

American College of Cardiology

SEPTEMBER 26, 2024

Does semaglutide efficacy vary with baseline diuretic use and does semaglutide change diuretic dose in patients with heart failure with preserved ejection fraction (HFpEF)?

Preserved Ejection Fraction 63

Preserved Ejection Fraction Obesity Heart Failure Article 63

Med Page Today

APRIL 7, 2024

(MedPage Today) -- ATLANTA -- Weight loss and heart failure benefits with semaglutide (Wegovy) extended to patients with obesity-related heart failure with preserved ejection fraction (HFpEF) who have type 2 diabetes, the STEP-HFpEF DM trial showed.

Preserved Ejection Fraction 72

Preserved Ejection Fraction Diabetes Heart Failure Obesity 72